Visakhapatnam: Nearly one in 12 people living with HIV in Andhra Pradesh who successfully completed tuberculosis (TB) treatment developed another episode of the disease within two years, while more than 15% died during the same period, highlighting the continuing risks faced by patients even after completing treatment.Nearly 67% of recurrent TB cases occurred within the first year, with the risk particularly high during the initial six months, according to a study by researchers from US Centers for Disease Control and Prevention (CDC), Andhra Pradesh State AIDS Control Society, and Society for Health Allied Research and Education India (SHARE India), Hyderabad.The findings underscore the need for continued monitoring and comprehensive HIV care after TB treatment, rather than considering treatment completion the end of clinical follow-up.
Unsuppressed HIV viral loads, lack of dolutegravir-based antiretroviral therapy (ART), and delayed or missed TB preventive therapy were among the factors associated with a higher risk of recurrent TB.The retrospective cohort study tracked 3,357 people living with HIV who completed TB treatment between 2017 and 2021 at 14 ART centres across three high-burden districts — East Godavari, Krishna and Guntur.
The participants were followed for two years after completing TB treatment, with follow-up extending until Dec 31, 2023.During this period, 270 participants (8%) developed recurrent TB, while 510 (15.2%) died. Another 408 (12.2%) were lost to follow-up, while 2,439 (72.6%) remained on ART. The median time to recurrent TB was seven months after treatment completion, while the median time to death was eight months.The concentration of recurrent cases in the initial months was particularly striking.
Of the 270 patients who developed TB again,
Of the 270 patients who developed TB again, 118 (43.7%) did so within six months of completing treatment and 181 (67%) within 12 months.Deaths also occurred relatively early. Of the 510 deaths recorded during follow-up, 167 (32.7%) occurred within six months of treatment completion and 211 (41.4%) within a year.Unsuppressed HIV viral load emerged as one of the strongest factors associated with recurrent TB and mortality.
Participants with HIV viral loads of 1,000 copies per ml or higher had 3.36 times the adjusted hazard of recurrent TB compared with those whose viral loads were suppressed. Their adjusted hazard of death was also 3.71 times higher.The type and duration of ART were also significant. Participants who had not received dolutegravir-based ART had 2.62 times the adjusted hazard of recurrent TB compared with those who had received the regimen for more than 12 months.
Their adjusted hazard of death was 2.77 times higher.The researchers also examined the uptake and timing of secondary TB preventive therapy, which is recommended for eligible adults after successful TB treatment and the exclusion of active disease. Only 43% of participants initiated preventive therapy within nine months of completing TB treatment, while 35.7% did not receive it.Those who started preventive therapy after nine months, or did not receive it at all, had higher adjusted hazards of recurrent TB than those who initiated it within nine months.
The researchers cautioned against interpreting this association
However, the researchers cautioned against interpreting this association as proof of the therapy’s effectiveness, noting that differences in survival and continued engagement with HIV care could have influenced the findings.National guidelines recommend follow-up assessments at six, 12, 18 and 24 months after completion of TB treatment. These assessments include screening for TB symptoms and further molecular testing when the disease is suspected.
The researchers said the findings reinforce the need for more intensive monitoring during the first year after treatment, alongside uninterrupted ART, regular HIV viral load testing and timely initiation of TB preventive therapy.The study — titled ‘Recurrent Tuberculosis Among People Living with HIV in a High-Burden Setting of Andhra Pradesh, India, 2017–2023: Findings from a Cohort Study’ — was published in the international journal Open Forum Infectious Diseases.
The authors include Ramesh Allam, Manjula Thogarucheeti, Nalini Chava and 12 other researchers affiliated with US CDC’s Division of Global HIV and TB, New Delhi; Andhra Pradesh State AIDS Control Society, Vijayawada; and SHARE India, Hyderabad.The researchers acknowledged several limitations, including the reliance on routinely collected programme data from just three districts and the inability to distinguish between TB relapse and reinfection.
They emphasised that completing TB treatment should not signal the end of medical care for people living with HIV. The first year after treatment, in particular, remains a critical period requiring close clinical surveillance and sustained HIV management.You Can Also Check: Gold Rate in Vijayawada | Silver Rate in Vijayawada | Bank Holidays in Vijayawada | Public Holidays in Vijayawada | Petrol Price in Vijayawada | Diesel Price in Vijayawada | CNG Price in Vijayawada | LPG Price in VijayawadaStay updated with the latest Vijayawada news.
Download the TOI App.





